Because the presence of EGFR mutations in general is predictive of responsiveness to EGFR tyrosine kinase inhibitors, adenocarcinoma or NSCLC not otherwise specified should be tested for such alterations [40]. This evidence concerns the gene EGFR and adenocarcinoma.